Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895215 · ClinicalTrials.gov registry record · Phase 2
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
A Phase 2 study of Autism Spectrum Disorder (ASD), sponsored by Vertero Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT04895215: Completed Phase 2 study of Autism Spectrum Disorder (ASD), sponsored by Vertero Therapeutics.
NCT04895215 is a Phase 2 study of Autism Spectrum Disorder (ASD) that has completed, run by Vertero Therapeutics. The registered enrollment target is 156 participants, above the 93-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895215, a Phase 2 study of Autism Spectrum Disorder (ASD), has completed, sponsored by Vertero Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AB-2004
Study Locations (20)
Florida
- CNS Solutions - Jacksonville
- CNS Solutions - Orlando
- University of South Florida - Tampa
Arizona
- Southwestern Autism Research and Resource Center - Phoenix
- University of Arizona - Tucson
California
- Cortica Marin - San Rafael
- Cortica Westlake - Westlake Village
New York
- Spectrum Neuroscience and Treatment Institute - New York
- Nathan S. Kline Institute for Psychiatric Research - Orangeburg
New South Wales
- Brain Mind Centre - Sydney
- Westmead Children's Hospital - Sydney
Alabama
- Harmonex Neuroscience Research - Dothan
Colorado
- IMMUNOe Research Centers - Centennial
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
What the finished NCT04895215 record still lists
NCT04895215 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (68% higher).
The record links to 1 condition, with Autism Spectrum Disorder (ASD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04895215 names 20 study sites across 14 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04895215 about?
NCT04895215 is a clinical study titled "AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)". The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
What is the current status of trial NCT04895215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2021-08-02. Estimated completion is 2023-12-15.
What conditions does trial NCT04895215 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder (ASD).
What interventions are being tested in trial NCT04895215?
The interventions under investigation include: Placebo (DRUG), AB-2004 (DRUG).
Who is sponsoring clinical trial NCT04895215?
This trial is sponsored by Vertero Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895215 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder (ASD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04895215's enrollment target sits among peer trials
156 4th of 16 higher than 13 of 16 other Autism Spectrum Disorder (ASD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder (ASD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
RECRUITING · Phase 2
-
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
COMPLETED · Phase 2
-
ADAPT: Approach to Dance for Autism
RECRUITING · NA
-
External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms
RECRUITING · NA
-
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
RECRUITING · Phase 1
-
Sleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI